223 related articles for article (PubMed ID: 17894706)
1. Intermittent vs. continuous 1-year cyclosporin use in chronic plaque psoriasis.
Chaidemenos GC; Mourellou O; Avgoustinaki N; Papakonstantinou M; Karakatsanis G; Katsambas A
J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1203-8. PubMed ID: 17894706
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
Menter A; Feldman SR; Weinstein GD; Papp K; Evans R; Guzzo C; Li S; Dooley LT; Arnold C; Gottlieb AB
J Am Acad Dermatol; 2007 Jan; 56(1):31.e1-15. PubMed ID: 17097378
[TBL] [Abstract][Full Text] [Related]
4. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
5. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study.
Ho VC; Griffiths CE; Berth-Jones J; Papp KA; Vanaclocha F; Dauden E; Beard A; Puvanarajan L; Paul C
J Am Acad Dermatol; 2001 Apr; 44(4):643-51. PubMed ID: 11260540
[TBL] [Abstract][Full Text] [Related]
6. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
Yoon HS; Youn JI
J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
8. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy.
Ozawa A; Sugai J; Ohkido M; Ohtsuki M; Nakagawa H; Kitahara H; Tamaki K; Urabe K; Nakayama J; Horikoshi T; Morimoto Y; Jimbow K
Eur J Dermatol; 1999; 9(3):218-23. PubMed ID: 10210789
[TBL] [Abstract][Full Text] [Related]
12. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
Ohtsuki M; Nakagawa H; Sugai J; Ozawa A; Ohkido M; Nakayama J; Hanada J; Morimoto Y; Jimbow K; Horikoshi T; Kitahara H; Tamaki K; Urabe K; Hori Y
J Dermatol; 2003 Apr; 30(4):290-8. PubMed ID: 12707465
[TBL] [Abstract][Full Text] [Related]
13. Intermittent cyclosporin A treatment of severe plaque psoriasis. Long-term follow-up of 26 patients.
Peluso AM; Bardazzi F; Tosti A; Varotti C
Acta Derm Venereol Suppl (Stockh); 1994; 186():90-1. PubMed ID: 8073851
[TBL] [Abstract][Full Text] [Related]
14. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
[TBL] [Abstract][Full Text] [Related]
15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness and patient satisfaction for treatment with low-dose cyclosporin administration in patients with moderate psoriasis vulgaris.
Abe M; Ishibuchi H; Syuto T; Sogabe Y; Yokoyama Y; Ishikawa O
J Dermatol; 2007 May; 34(5):290-3. PubMed ID: 17408436
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study.
Berth-Jones J; Henderson CA; Munro CS; Rogers S; Chalmers RJ; Boffa MJ; Norris PG; Friedmann PS; Graham-Brown RA; Dowd PM; Marks R; Sumner MJ
Br J Dermatol; 1997 Apr; 136(4):527-30. PubMed ID: 9155952
[TBL] [Abstract][Full Text] [Related]
18. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
Krueger GG; Elewski B; Papp K; Wang A; Zitnik R; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis.
Lago E; Carneiro S; Cuzzi T; Magalhães G; Cássia F; Pessanha F; Ramos-e-Silva M
J Cutan Pathol; 2007 Jan; 34(1):15-21. PubMed ID: 17214849
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2).
Reich K; Wozel G; Zheng H; van Hoogstraten HJ; Flint L; Barker J
Br J Dermatol; 2013 Jun; 168(6):1325-34. PubMed ID: 23621698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
